|Healthcare Review: STAAR Surgical Company, Keryx Biopharmaceuticals, VIVUS, Synta Pharmaceuticals, Affymetrix|
|By Staff and Wire Reports|
|Tuesday, 09 April 2013 13:40|
Following are notable movers:
STAAR Surgical Company (NASDAQ:STAA) shares increased 13.25% to $6.24. The company, on April 8, announced that first quarter revenue is expected to be approximately $18 million.
STAAR is reporting the preliminary results due to previously scheduled meetings with investors on April 11-12 and the upcoming American Society of Cataract and Refractive Surgeons Annual Conference. Final results for the first quarter are expected to be released on May 1, 2013.
Keryx Biopharmaceuticals (NASDAQ:KERX) shares grew 11.51% to $8.18. The company, on Marc h 11, 2013 announced its results for the fourth quarter and year ended December 31, 2012. The net loss for the 4th quarter ended December 31, 2012 was $6.6 million, or $0.09 per share versus $8.4 million for quarter 2011, representing a decrease of $1.8 million and Net loss for the year ended December 31, 2012, was $22.7 million versus $28.1 million for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million. At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.
VIVUS, Inc. (NASDAQ:VVUS) shares climbed 4.78% to $10.96. The company, on March 26, announced that it has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors. Under the terms of this financing, VIVUS will make an initial draw of $50 million and will have the option, at its discretion, to draw an additional $60 million at any time prior to December 31, 2013.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares gained 4.30 % to $10.42. The company, on April 5, reported that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, will be presented at the 2013 Annual Meeting of the American Association of Cancer Research in Washington, D.C.
Affymetrix, Inc. (NASDAQ:AFFX) shares decreased 13.41% to $4.03. The company today reported that based on preliminary financial data, the Company expects total revenue of approximately $78 million for the first quarter of 2013, including revenue of approximately $19 million from eBioscience. The Company expects to report cash-on-hand of at least $38 million as of March 31, 2013.
Additionally, Ingenuity® Systems and Affymetrix on April 8 announced that they will co-promote Ingenuity® iReport(TM) with Affymetrix expression microarray products effectively eliminating a bottleneck for researchers working with human, mouse and rat applications by coupling a fast and accurate statistical analysis and biological interpretation workflow with the gold-standard platform for gene expression studies.